Cagrisema.

Cagrisema is an investigational compound in the glp-1 & incretin receptor agonists.

Its biological effect is described in the mechanism section.

It draws interest for glp-1 & incretin receptor agonists.

C-tier evidence: some human evidence exists but isn't definitive.

What it is

CagriSema is a fixed-combination injectable investigational obesity therapeutic developed by Novo Nordisk that co-formulates two long-acting peptide analogues in a single once-weekly subcutaneous injection: cagrilintide, a long-acting amylin receptor agonist (analogue of the pancreatic hormone amylin), and semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist already marketed for diabetes and obesity. It pairs the same semaglutide molecule found in Ozempic and Wegovy with a novel amylin analogue, making it the first amylin-plus-GLP-1 dual-hormone combination to reach late-stage clinical development for weight management.

How it works

The two components act on complementary appetite-regulating pathways. Semaglutide is a GLP-1 receptor agonist that slows gastric emptying and signals through hypothalamic and brainstem circuits to reduce hunger and increase satiety. Cagrilintide is an amylin analogue that engages amylin and calcitonin-family receptors, also acting on the area postrema and hypothalamus to promote satiation and reduce food intake; amylin signaling is thought to modulate leptin sensitivity and meal termination through a partly distinct mechanism from GLP-1. The rationale is that combining the two yields additive or complementary reductions in energy intake beyond either agent alone.

What the evidence shows

Unlike most "research peptides," CagriSema has substantial human Phase 3 data from the REDEFINE program. In REDEFINE 1 (Garvey et al., NEJM 2025; 68 weeks, ~3,400 adults with obesity/overweight without diabetes), CagriSema produced roughly 20% mean body-weight loss versus semaglutide alone, cagrilintide alone, and placebo. In REDEFINE 2 (Davies et al., NEJM 2025), conducted in adults with overweight/obesity and type 2 diabetes, CagriSema reduced body weight and HbA1c versus placebo, though weight loss in the diabetes population was more modest, consistent with the general pattern for incretin therapies. REDEFINE 5 (Yamauchi et al., Lancet Diabetes & Endocrinology 2026) evaluated it versus semaglutide alone in Japan and Taiwan. Importantly, in the open-label head-to-head REDEFINE 4 trial, CagriSema (~23% weight loss on the efficacy estimand) did NOT meet its primary endpoint of non-inferiority versus tirzepatide (Zepbound, ~25.5%) — a notable negative result that tempers claims of clear superiority over existing dual/incretin therapies.

Safety considerations

The most common adverse events in the REDEFINE trials were gastrointestinal — nausea, vomiting, diarrhea, and constipation — consistent with the known class effects of GLP-1 receptor agonists and amylin analogues; these were generally mild-to-moderate and most frequent during dose escalation. As with other GLP-1-based therapies, label-level concerns for the class include gallbladder events, pancreatitis risk signals, and a boxed thyroid C-cell tumor warning carried by semaglutide products (based on rodent data). Long-term safety, durability after discontinuation, and outcomes in broader real-world populations remain incompletely characterized because the compound is still investigational and only recently filed for approval. No legitimate medical use exists outside clinical trials and (pending) regulatory approval, and gray-market "research" cagrilintide/semaglutide products carry purity, sterility, and dosing-error risks.

Regulatory status

CagriSema is investigational and not approved by the FDA or EMA as of mid-2026; Novo Nordisk submitted a U.S. New Drug Application for chronic weight management on December 18, 2025, with a regulatory decision anticipated in late 2026. Its individual components have separate statuses — semaglutide is FDA-approved (e.g., Wegovy, Ozempic), while cagrilintide alone is not approved.

1. [1]Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1) — New England Journal of Medicine, 2025, Garvey WT et al., PMID 40544433
2. [2]Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2) — New England Journal of Medicine, 2025, Davies MJ et al., PMID 40544432
3. [3]Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5) — Lancet Diabetes & Endocrinology, 2026, Yamauchi T et al., PMID 42009015
4. [4]Novo Nordisk files for FDA approval of CagriSema (NDA submission, Dec 2025) — Novo Nordisk / PR Newswire, 2025

• Investigational; not FDA-approved.
• Benefit and tolerability versus single agents are not yet settled.

Stack fit

Why not B: held back by regulatory clarity.

Why not D: supported by its overall evidence profile.

What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.

What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.

• Cagrisema is not FDA-approved for human use; it is discussed in a research context.
• It belongs to the GLP-1 & incretin receptor agonists class.

• Whether observed effects reliably translate to humans at large.
• Long-term safety in healthy users, and full drug-interaction risk.
• Optimal studied parameters outside any approved indication.
• Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
• Quality and purity of material from non-pharmaceutical sources.

1. What it is
2. The preclinical evidence lane
3. Why Early, and not higher or lower
4. Proven lane vs speculative lane
5. What people report
6. Regulatory status
7. What changed recently